Literature DB >> 26517058

Postoperative imaging for detection of recurrent arteriovenous malformations in children.

Peter F Morgenstern1, Caitlin E Hoffman1, Gary Kocharian2, Ranjodh Singh2, Philip E Stieg1,2, Mark M Souweidane1,2.   

Abstract

OBJECT The optimal method for detecting recurrent arteriovenous malformations (AVMs) in children is unknown. An inherent preference exists for MR angiography (MRA) surveillance rather than arteriography. The validity of this strategy is uncertain. METHODS A retrospective chart review was performed on pediatric patients treated for cerebral AVMs at a single institution from 1998 to 2012. Patients with complete obliteration of the AVM nidus after treatment and more than 12 months of follow-up were included in the analysis. Data collection focused on recurrence rates, associated risk factors, and surveillance methods. RESULTS A total of 45 patients with a mean age of 11.7 years (range 0.5-18 years) were treated for AVMs via surgical, endovascular, radiosurgical, or combined approaches. Total AVM obliteration on posttreatment digital subtraction angiography (DSA) was confirmed in 27 patients, of whom the 20 with more than 12 months of follow-up were included in subsequent analysis. The mean follow-up duration in this cohort was 5.75 years (median 5.53 years, range 1.11-10.64 years). Recurrence occurred in 3 of 20 patients (15%). Two recurrences were detected by surveillance DSA and 1 at the time of rehemorrhage. No recurrences were detected by MRA. Median time to recurrence was 33.6 months (range 19-71 months). Two patients (10%) underwent follow-up DSA, 5 (25%) had DSA and MRI/MRA, 9 (45%) had MRI/MRA only, 1 (5%) had CT angiography only, and 3 (15%) had no imaging within the first 3 years of follow-up. After 5 years posttreatment, 2 patients (10%) were followed with MRI/MRA only, 2 (10%) with DSA only, and 10 (50%) with continued DSA and MRI/MRA. CONCLUSIONS AVM recurrence in children occurred at a median of 33.6 months, when MRA was more commonly used for surveillance, but failed to detect any recurrences. A recurrence rate of 15% may be an underestimate given the reliance on surveillance MRA over angiography. A new surveillance strategy is proposed, taking into account exposure to diagnostic radiation and the potential for catastrophic rehemorrhage.

Entities:  

Keywords:  AChA = anterior choroidal artery; AVM = arteriovenous malformation; CTA = CT angiography; DSA = digital subtraction angiography; EVD = external ventricular drain; ICA = internal carotid artery; ICH = intracerebral hemorrhage; MRA = MR angiography; arteriovenous malformation; cerebral angiography; mRS = modified Rankin Scale; magnetic resonance imaging; recurrence; vascular disorders

Year:  2015        PMID: 26517058     DOI: 10.3171/2015.6.PEDS14708

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  10 in total

1.  Predictive Value of MRI in Diagnosing Brain AVM Recurrence after Angiographically Documented Exclusion in Children.

Authors:  A Jhaveri; A Amirabadi; P Dirks; A V Kulkarni; M M Shroff; N Shkumat; T Krings; V M Pereira; V Rea; P Muthusami
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

Review 2.  Management of intracerebral hemorrhage in pediatric neurosurgery.

Authors:  Visish M Srinivasan; Loyola V Gressot; Bradley S Daniels; Jeremy Y Jones; Andrew Jea; Sandi Lam
Journal:  Surg Neurol Int       Date:  2016-12-28

3.  Differences in bleeding patterns and outcome after intracerebral hemorrhage due to vascular malformations.

Authors:  Nazife Dinc; Sae-Yeon Won; Nina Brawanski; Michael Eibach; Johanna Quick-Weller; Jürgen Konczalla; Joachim Berkefeld; Volker Seifert; Gerhard Marquardt
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

Review 4.  Ruptured Arteriovenous Malformation Anterior to the Brainstem to a Child with Subsequent Spontaneous Thrombosis: Case Report and Literature Review.

Authors:  Dimitrios Panagopoulos; Georgios Markogiannakis; Marios Themistocleous
Journal:  Am J Case Rep       Date:  2020-05-01

5.  Children with Arteriovenous Malformations of the Central Nervous System: A Retrospective Study of 12 Pediatric Cases from a Single Tertiary Center in Slovenia.

Authors:  Ula Arkar; Tina Vipotnik Vesnaver; Anja Troha Gergeli; Neli Bizjak; Damjan Osredkar
Journal:  Med Sci Monit       Date:  2022-03-06

6.  Venous Outflow for Brain Arteriovenous Malformations: Overview and Treatment Implications.

Authors:  C Osorno-Cruz; Z Hasanpour; R Peart; W Dodd; D Laurent; S Aghili-Mehrizi; B Lucke-Wold; N Chalouhi
Journal:  Int J Neurobiol       Date:  2022-08-16

7.  Validation of computed tomography angiography as a complementary test in the assessment of renal artery stenosis: a comparison with digital subtraction angiography.

Authors:  Anilawan S Fleury; Rachelle E Durand; Anne Marie Cahill; Xiaowei Zhu; Kevin E Meyers; Hansel J Otero
Journal:  Pediatr Radiol       Date:  2021-08-10

8.  Cerebral Arteriovenous Malformation Recurrence After Complete Surgical Excision in an Adult: Case Report and Review of the Literature.

Authors:  Daniel Loh; Vincent Ng
Journal:  Cureus       Date:  2021-06-01

Review 9.  Chinese Cerebrovascular Neurosurgery Society and Chinese Interventional & Hybrid Operation Society, of Chinese Stroke Association Clinical Practice Guidelines for Management of Brain Arteriovenous Malformations in Eloquent Areas.

Authors:  Mingze Wang; Yuming Jiao; Chaofan Zeng; Chaoqi Zhang; Qiheng He; Yi Yang; Wenjun Tu; Hancheng Qiu; Huaizhang Shi; Dong Zhang; Dezhi Kang; Shuo Wang; A-Li Liu; Weijian Jiang; Yong Cao; Jizong Zhao
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

10.  Comparison of the Long-term Efficacy and Safety of Gamma Knife Radiosurgery for Arteriovenous Malformations in Pediatric and Adult Patients.

Authors:  Hirotaka Hasegawa; Shunya Hanakita; Masahiro Shin; Mariko Kawashima; Wataru Takahashi; Osamu Ishikawa; Satoshi Koizumi; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-17       Impact factor: 1.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.